A potential U.S. Drug Enforcement Administration move to reclassify marijuana could remove key tax burdens for Canopy Growth and peers.
Canopy Growth (NASDAQ: CGC) and other cannabis stocks await a U.S. Drug Enforcement Administration (DEA) decision on rescheduling marijuana to Schedule III. The move, if approved, would eliminate Section 280E tax deductions, easing financial pressures on U.S. operations like Canopy USA.
Legal experts expect a favorable outcome following recent hearings, though timing remains uncertain. President Trump’s December executive order urged expedited action, raising hopes for a near-term resolution. Rescheduling would not resolve all regulatory hurdles but could trigger a sector-wide rally.
Market reaction hinges on the DEA’s final ruling, with investors weighing entry points ahead of the announcement.